Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prescient Therapeutics Limited ( (AU:PTX) ) has provided an announcement.
Prescient Therapeutics Limited announced a change in the director’s interest, with Melanie Farris acquiring 250,000 fully paid ordinary shares through an on-market trade. This transaction reflects a significant personal investment by a key company leader, potentially indicating confidence in the company’s future prospects and strategic direction.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cancer therapies. The company specializes in targeted and personalized medicine, aiming to improve treatment outcomes for cancer patients.
YTD Price Performance: -8.00%
Average Trading Volume: 610,533
Technical Sentiment Signal: Hold
Current Market Cap: A$37.04M
Learn more about PTX stock on TipRanks’ Stock Analysis page.